High Prevalence of Multi-Drug Resistance and Extended Spectrum Beta Lactamase Production in Non-Fermenting Gram-Negative Bacilli in Ethiopia.
Multi-drug resistance
Non-Fermentative Gram-Negative Bacilli
carbapenemase
extended spectrum beta lactamase
Journal
Infectious diseases
ISSN: 1178-6337
Titre abrégé: Infect Dis (Auckl)
Pays: United States
ID NLM: 101603964
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
09
2019
accepted:
06
10
2019
entrez:
15
11
2019
pubmed:
15
11
2019
medline:
15
11
2019
Statut:
epublish
Résumé
Emergence of resistance to multiple antimicrobial agents in Non-Fermenting Gram-Negative Bacilli is a major problem to public health, as it limits drug treatment options against infections. The aim of this study was to determine the prevalence of multi-drug resistance and extended spectrum beta lactamase production in Non-Fermenting Gram-Negative Bacilli. Different clinical samples were collected and processed following standard procedures. Each sample was then inoculated onto culture media. Identification, drug susceptibility testing, and extended spectrum beta lactamase production of the isolates were carried out by using the VITEK 2 compact system. Among 996 clinical samples, 135 samples yielded Non-Fermenting Gram-Negative Bacilli of which The spectrum of bacterial species isolated was diverse. The isolates demonstrated high level of drug resistance in different classes of antibiotics. The magnitude of multi-drug resistance and the level of extended spectrum beta lactamase production were high. Hence, further studies on multi-drug resistant and extended spectrum beta lactamase producing Non-Fermenting Gram-Negative Bacilli both in the community and in hospital setting are essential.
Sections du résumé
BACKGROUND
BACKGROUND
Emergence of resistance to multiple antimicrobial agents in Non-Fermenting Gram-Negative Bacilli is a major problem to public health, as it limits drug treatment options against infections. The aim of this study was to determine the prevalence of multi-drug resistance and extended spectrum beta lactamase production in Non-Fermenting Gram-Negative Bacilli.
MATERIALS AND METHODS
METHODS
Different clinical samples were collected and processed following standard procedures. Each sample was then inoculated onto culture media. Identification, drug susceptibility testing, and extended spectrum beta lactamase production of the isolates were carried out by using the VITEK 2 compact system.
RESULTS
RESULTS
Among 996 clinical samples, 135 samples yielded Non-Fermenting Gram-Negative Bacilli of which
CONCLUSIONS
CONCLUSIONS
The spectrum of bacterial species isolated was diverse. The isolates demonstrated high level of drug resistance in different classes of antibiotics. The magnitude of multi-drug resistance and the level of extended spectrum beta lactamase production were high. Hence, further studies on multi-drug resistant and extended spectrum beta lactamase producing Non-Fermenting Gram-Negative Bacilli both in the community and in hospital setting are essential.
Identifiants
pubmed: 31723320
doi: 10.1177/1178633719884951
pii: 10.1177_1178633719884951
pmc: PMC6836305
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178633719884951Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Australas Med J. 2013 Dec 31;6(12):697-700
pubmed: 24391681
Iran J Pathol. 2015 Fall;10(4):265-71
pubmed: 26351496
J Med Microbiol. 2009 May;58(Pt 5):596-605
pubmed: 19369521
Antimicrob Agents Chemother. 1999 Jun;43(6):1379-82
pubmed: 10348756
Int J Antimicrob Agents. 2012 Jun;40 Suppl:S37-43
pubmed: 22749057
Clin Infect Dis. 2006 Mar 1;42(5):692-9
pubmed: 16447117
J Infect Public Health. 2013 Jun;6(3):179-85
pubmed: 23668462
Clin Microbiol Rev. 2008 Jul;21(3):538-82
pubmed: 18625687
J Clin Microbiol. 2000 Feb;38(2):570-4
pubmed: 10655347
Indian J Med Sci. 2000 Mar;54(3):87-91
pubmed: 11227617
J Med Microbiol. 2001 Jul;50(7):642-5
pubmed: 11444775
Asian Pac J Trop Med. 2015 Jun;8(6):438-46
pubmed: 26194827
Epidemiol Infect. 2011 Nov;139(11):1740-9
pubmed: 21226988
Clin Infect Dis. 2001 May 15;32 Suppl 2:S104-13
pubmed: 11320451
J Microbiol Immunol Infect. 2015 Feb;48(1):92-100
pubmed: 24060496
Int J Infect Dis. 2008 May;12(3):312-8
pubmed: 18032082
Indian J Pathol Microbiol. 2011 Jul-Sep;54(3):666-7
pubmed: 21934266
J Lab Physicians. 2009 Jul;1(2):62-6
pubmed: 21938252
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Crit Care. 2011;15(2):215
pubmed: 21457501
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
J Clin Microbiol. 2006 Sep;44(9):3257-62
pubmed: 16954257
Pak J Med Sci. 2013 Sep;29(5):1253-8
pubmed: 24353731
J Chemother. 2001 Jun;13(3):260-4
pubmed: 11450883
Am J Infect Control. 2006 Jun;34(5 Suppl 1):S29-37; discussion S64-73
pubmed: 16813979
Pan Afr Med J. 2014 Oct 21;19:177
pubmed: 25815098
Indian J Med Res. 2007 Jul;126(1):63-7
pubmed: 17890826
J Glob Infect Dis. 2016 Oct-Dec;8(4):155-159
pubmed: 27942195
Antimicrob Agents Chemother. 2003 May;47(5):1749-51
pubmed: 12709353
J Infect Dis. 2008 Apr 15;197(8):1079-81
pubmed: 18419525
Antimicrob Resist Infect Control. 2017 Oct 23;6:106
pubmed: 29075483
Antimicrob Agents Chemother. 1996 Jun;40(6):1412-8
pubmed: 8726011
Ann Clin Microbiol Antimicrob. 2015 Feb 03;14:7
pubmed: 25643932
Clin Infect Dis. 1997 Nov;25(5):1094-8
pubmed: 9402364
J Hosp Infect. 2007 Mar;65(3):204-11
pubmed: 17254667